Lecture Summary - ESMO 2022 on the Updated Analysis of DESTINY-Gastric02: A Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan in Western Patients With HER2+ Unresectable/Metastatic Gastric/Gastroesophageal Junction Cancer Who Progressed on or After Trastuzumab-Containing Regimen

9 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login